{
    "clinical_study": {
        "@rank": "41936", 
        "brief_summary": {
            "textblock": "This study will evaluate the association of non-alcoholic fatty liver disease and diabetes\n      mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive\n      the following examination:\n\n        -  Transient Elastography and Controlled Attenuation Parameter using the FibroScan\n\n        -  blood examination including biochemical markers The statistically calculated sample\n           size needed is 340 patients."
        }, 
        "brief_title": "ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-alcoholic Fatty Liver Disease (NAFLD)", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Fatty Liver", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 years and older\n\n          -  Written informed consent\n\n          -  Diabetes mellitus type 1 or 2\n\n        Exclusion Criteria:\n\n          -  Patients with mental diseases\n\n          -  Pregnancy or lactation\n\n          -  Ascites\n\n          -  Continued alcohol consumption (> 21 drinks/week for male and > 14 drinks/week for\n             female patients)\n\n          -  Chronic liver disease (viral hepatitis, autoimmune hepatitis, PBC, PSC,\n             hemochromatosis, M Wilson)\n\n          -  Hepatocellular carcinoma/ Liver metastasis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997424", 
            "org_study_id": "JWGUHMED1-007"
        }, 
        "intervention": [
            {
                "intervention_name": "Controlled Attenuation Parameter (CAP), Echosens, Paris, France", 
                "intervention_type": "Device"
            }, 
            {
                "intervention_name": "FibroScan, Echosens, Paris, France", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 27, 2013", 
        "location": {
            "contact": {
                "last_name": "Mireen Friedrich-Rust, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt am Main", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60590"
                }, 
                "name": "University Hospital Frankfurt"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS", 
        "overall_contact": {
            "last_name": "Mireen Friedrich-Rust, MD", 
            "phone": "496963015122"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Frankfurt", 
            "last_name": "Mireen Friedrich-Rust, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tEvaluating the presence of liver steatosis in patients with diabetes mellitus using the ultrasound-based method \"Controlled Attenuation Parameter\", which is integrated in the FibroScan machine and can non-invasively quantify liver steatosis (Steatosis fibrosis scores I-III [ Designated as safety issue: No ]; Steatosis scores: 0 = <5% I = 5-33% II = 33-66% III = >66%)", 
            "measure": "Steatosis", 
            "safety_issue": "No", 
            "time_frame": "one day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997424"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "investigator_full_name": "Johannes Vermehren", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tEvaluation of the prevalence of liver fibrosis using transientelastography (FibroScan) and serological markers in patients with diabetes mellitus (Liver fibrosis scores I-IV (METAVIR) [ Designated as safety issue: No ]; METAVIR fibrosis scores: I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis)", 
                "measure": "Fibrosis", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }, 
            {
                "description": "\u2022\tEvaluating the prevalence of liver steatosis using serum steatosis markers in patients with diabetes mellitus", 
                "measure": "Steatosis (serum)", 
                "safety_issue": "No", 
                "time_frame": "one day"
            }
        ], 
        "source": "Johann Wolfgang Goethe University Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johann Wolfgang Goethe University Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}